Holen Sie sich die Stockscreener-App
137.37
1.25%
1.70
Vorhandelsmarkt:
137.98
0.61
+0.44%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt BIIB?
Forum
Prognose
Aktiensplit
Biogen Inc Aktie (BIIB) Neueste Nachrichten
Biogen, Eisai Say China Approves Maintenance Dosing Regimen for Alzheimer's Drug - MarketScreener
“LEQEMBI®” (lecanemab) IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease Approved in China - Biogen
Biogen (BIIB) Secures Approval for LEQEMBI's Monthly Dosing in C - GuruFocus
Eisai and Biogen Announce Approval of LEQEMBI® for Maintenance Dosing in Alzheimer's Disease Treatment in China - Quiver Quantitative
Biogen Inc. (BIIB): A Bull Case Theory - Yahoo
What drives Biogen Inc stock priceMomentum Stock Picks & Bull Bear Market Updates - earlytimes.in
What analysts say about Biogen Inc IDP stockInstitutional Buying Trends & Minimal Investment Trading Plans - Early Times
A Look at Biogen’s (BIIB) Valuation Following FDA Feedback on Spinraza High-Dose Application - simplywall.st
Biogen (BIIB): Reevaluating Valuation Following FDA’s Supplemental Spinraza Dose Setback - Yahoo Finance
Biogen (BIIB) Expands Neurology Pipeline With Alcyone Buyout, Stock Seen Undervalued - Yahoo
Biogen CoLab sparks Harvard student's biotech career journeyBizwomen - The Business Journals
Fierce Biotech Layoff Tracker 2025: Heidelberg reduces headcount by 75%; Biogen trims team - Fierce Biotech
BIOGEN : TO REPORT THIRD QUARTER 2025 FINANCIAL RESULTS OCTOBER 30, 2025 - MarketScreener
Biogen to Report Third Quarter 2025 Financial Results October 30, 2025 - Biogen
Exclusive: Biogen calls it quits on AAV gene therapy, again - Endpoints News
What's Going On With Biogen StockBiogen (NASDAQ:BIIB) - Benzinga
Jefferies sees positive triggers for Biogen's stockinitiates with a buy rating. - MarketScreener
Jefferies bullish on Biogen Alzheimer’s drug, pipeline By Investing.com - Investing.com Canada
This Lululemon Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Thursday - Benzinga
This Biogen Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday - Benzinga
Jefferies Initiates Coverage of Biogen (BIIB) with Buy Recommendation - Nasdaq
National Ataxia Foundation Partners with Biogen to Bring Bill Nye "the Science Guy" Back To the Lab With New Series About Friedreich Ataxia - WV News
Jefferies Initiates Coverage on Biogen (BIIB) with Buy Rating | - GuruFocus
Jefferies initiates Biogen stock with Buy rating, $190 price target By Investing.com - Investing.com Nigeria
Jefferies initiates Biogen stock with Buy rating, $190 price target - Investing.com India
Biogen, Eisai win regulatory nod in Australia for Alzheimer’s treatment - medwatch.com
United States Inflammatory Bowel Disease Market Growth Fueled - openPR.com
Biogen Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Biogen at Bernstein Insights: Strategic Pipeline Focus - Investing.com
Viatris Nixes Biogen's Extra 1-Year Protection Over MS Drug - Law360
Biogen’s high-dose Spinraza turned down by FDA due to CMC troubles - Yahoo Finance
BIIB's sNDA for Higher Dose of SMA Drug Spinraza Gets FDA's CRL - Yahoo Finance
FDA denies approval for higher dose of nusinersen for SMA - SMA News Today
EU judges cut Biogen’s monopoly on multiple sclerosis drug Tecfidera - Courthouse News
Biogen (NASDAQ:BIIB) Receives "Hold" Rating from Needham & Company LLC - MarketBeat
Australian Approval Boosts Biogen (BIIB) Alzheimer's Treatment - GuruFocus
Biogen (BIIB) Faces Minor Setback with FDA Response on Spinraza Dosage - GuruFocus
Biogen gets ‘unexpected’ CRL for high-dose Spinraza, will submit more technical data - Endpoints News
LEQEMBI® (Lecanemab) Approved for the Treatment of Alzheimer’s Disease in Australia - GlobeNewswire
425,000 Patients Affected: Australia Approves LEQEMBI for Early Alzheimer's Disease Treatment - Stock Titan
Biogen gets CRL for high dose nusinersen - The Pharma Letter
Biogen Inc. $BIIB Shares Bought by Parallel Advisors LLC - MarketBeat
Mn Services Vermogensbeheer B.V. Buys New Shares in Biogen Inc. $BIIB - MarketBeat
Biogen Inc. $BIIB Shares Sold by Swedbank AB - MarketBeat
Biogen complete response letter manageable, says Citi - TipRanks
Biogen (BIIB) Analyst Rating Reiterated as Hold by Needham | BII - GuruFocus
LEQEMBI(R) (Lecanemab) Approved for the Treatment of Alzheimer's Disease in Australia - JCN Newswire
FDA knocks back Biogen's high-dose Spinraza - pharmaphorum
Wall Street Zen Downgrades Biogen (NASDAQ:BIIB) to Buy - MarketBeat
FDA issues complete response letter for Biogen’s high-dose SMA drug - Investing.com Australia
FDA issues complete response letter for Biogen’s high-dose SMA drug By Investing.com - Investing.com South Africa
US FDA declines to approve higher dose of Biogen’s genetic disorder drug - 104.1 WIKY
US FDA declines to approve higher dose of Biogen's genetic disorder drug - Reuters
1.04%
0.77%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):